[Adverse effects of oral hypoglycemic agents].
Mori
Yasumichi
Y
Third Department of Internal Medicine, Yokohama City University, School of Medicine.
Sekihara
Hisahiko
H
D020909:Acarbose / Q000008:administration & dosage / Q000009:adverse effects; D000284:Administration, Oral; D001645:Biguanides / Q000008:administration & dosage / Q000009:adverse effects; D003510:Cyclohexanes / Q000009:adverse effects; D004347:Drug Interactions; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D000077715:Nateglinide; D010649:Phenylalanine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects; D045162:Thiazolidinediones
D001645:Biguanides; D003510:Cyclohexanes; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077715:Nateglinide; D010649:Phenylalanine; D020909:Acarbose; D000077205:Pioglitazone